RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
CAR T-Cell therapy shows promise against tough blood cancer
Disease control CompletedThis study tested a treatment called KTE-X19 (a type of CAR T-cell therapy) in 95 adults with mantle cell lymphoma that had come back or stopped responding to other treatments. The goal was to see if the therapy could shrink or eliminate the cancer. Participants received a one-ti…
Matched conditions: RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated May 26, 2026 12:04 UTC
-
Engineered immune cells show promise against tough blood cancer
Disease control CompletedThis study tested a treatment called KTE-X19 (brexucabtagene autoleucel) in 105 people with mantle cell lymphoma that had come back or stopped responding to other therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better attack cancer cells…
Matched conditions: RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated May 14, 2026 12:05 UTC